Sequenom Announces Leadership Appointments

                  Sequenom Announces Leadership Appointments

PR Newswire

SAN DIEGO, Dec. 11, 2012

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ --Sequenom, Inc. (Nasdaq: SQNM)
announced today the appointments of William Welch as the Company's President
and Chief Operating Officer and Dirk van den Boom as the Company's Executive
Vice President, Research & Development and Chief Technology Officer, both
effective immediately. Additionally, Ronald Lindsay has been named as the
Company's Executive Vice President, Strategic Planning. Harry F. Hixson, Jr.
will continue to serve as Chairman and Chief Executive Officer.

Mr. Welch joined Sequenom in January 2011 as Senior Vice President,
Diagnostics. He has overseen the Company's commercial operations in
connection with the October 2011 launch of its MaterniT21 PLUS
laboratory-developed test.

"Bill's extensive industry experience and knowledge have been a significant
asset to Sequenom over the last two years as we launched the MaterniT21 PLUS
test," said Harry Hixson, Jr., Chairman and Chief Executive Officer. "This
promotion reflects his many contributions to the growth of our company and the
board's confidence in his future leadership capacity."

Dr. van den Boom has served as Sequenom's Senior Vice President of research
and development since August 2010 and previously served as the Company's vice
president, research and development. He joined Sequenom in 1998 at the
company's Hamburg office, subsequently serving in various management roles of
increasing responsibility within the R&D department.

"Dirk has demonstrated impressive professional and managerial growth over the
past three years and we look forward to his contributions as he takes the helm
of R&D leadership at Sequenom," said Ronald M Lindsay, Director and newly
appointed EVP of Strategic Planning. "We believe Dirk will successfully drive
key strategic initiatives that will underpin the company's future growth."

Dr. Lindsay has served as Sequenom's Executive Vice President, Research &
Development since August 2010 and previously served as interim Senior Vice
President, Research and Development. Dr. Lindsay has served as a member of
Sequenom's Board of Directors since 2003.

Prior to joining Sequenom, Mr. Welch was a consultant to molecular diagnostic
companies in the personalized medicine sector. From August 2005 to September
2009, Mr. Welch was senior vice president and chief commercial officer at
Monogram Biosciences, a bioscience laboratory services company. Prior to his
time at Monogram, Mr. Welch was vice president of sales and marketing at La
Jolla Pharmaceuticals and vice president of global marketing with Dade Behring
MicroScan. Mr. Welch entered the healthcare field with Abbott Laboratories
where he held progressive management positions, including General Manager.
Mr. Welch earned a B.S. with honors in chemical engineering from the
University of California at Berkeley and received his M.B.A. from Harvard

Dr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the
University of Hamburg where he focused on various aspects of nucleic acid
analysis with mass spectrometry. He has co-authored more than 50 scientific
articles and is an inventor on 48 patents or patent applications.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding the Company's
expectations regarding future leadership and contributions, the Company's
future growth, and the Company's commitment to improving healthcare through
revolutionary genetic analysis solutions, are forward-looking statements
within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ materially,
including the risks and uncertainties associated with market demand for and
acceptance and use of technology and tests such as the MaterniT21 PLUS test,
reliance upon the collaborative efforts of other parties including without
limitation any international distributors or licensees, the Company or third
parties obtaining or maintaining regulatory approvals that impact the
Company's business, government regulation particularly with respect to
diagnostic products and laboratory developed tests, publication processes, the
performance of designed product enhancements, the Company's ability to develop
and commercialize technologies and products, particularly new technologies
such as noninvasive prenatal diagnostics, laboratory developed tests, and
genetic analysis platforms, the Company's financial position, the Company's
ability to manage its existing cash resources or raise additional cash
resources, competition, intellectual property protection and intellectual
property rights of others, litigation involving the Company, and other risks
detailed from time to time in the Company's filings with the Securities and
Exchange Commission, including without limitation its Quarterly Report on Form
10-Q for the quarter ended September 30, 2012 and its Annual Report on Form
10-K for the year ended December 31, 2011. These forward-looking statements
are based on current information that may change and you are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements are
qualified in their entirety by this cautionary statement, and the Company
undertakes no obligation to revise or update any forward-looking statement to
reflect events or circumstances after the issuance of this press release.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028,; or Jakob Jakobsen,
Media Contact, Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.